The target audience for this education program is all nurses who are responsible for the assessment and care of individuals who are being evaluated for or who use medical marijuana.
Marijuana as medicine has been embraced for thousands of years. It was listed in the United States Pharmacopeia from 1850 until 1942 to treat labor pains, nausea and rheumatism. Nonetheless, the DEA classified it as a Schedule 1 drug in 1970. Pharmacologically, it impacts the whole body, combining anxiolytic, sedative psychedelic and analgesic properties. In 2017, the National Institute of Drug Abuse (NIDA) describing the use of marijuana as a medicine. To date, FDA has not approved any medicinal products that are either derived from or contain botanical marijuana. Even so, in 1996, medical use of marijuana was legalized in California. In the past 20+ years, an additional 28 states have enacted their own laws allowing the medical use of marijuana. Potential applications include:
- Activity against some cancer cells
- Liberation from a variety of symptoms associated with AIDS.
- The American Academy of Neurology (AAN): Oral cannabis extract and synthetic THC are likely efficacious for reducing patient-reported symptoms of pain and spasticity associated with MS.
- Treatment of pain- with a more benign safety profile than opioids.
To guide good prescribing practices, it is critical to follow the scientific data. There is a paucity of well controlled clinical trials designed to show that marijuana can be effectively used. Moreover, there are potential liabilities associated with its use, especially when smoked. Recent research appears to argue for the use of specific analogues rather than whole marijuana. Although not well-supported by clinical research, the availability of medical marijuana is increasing. In addition to medical marijuana, generalized legalization of recreational marijuana is also on the upswing, paralleling overall increases in use. As a result, clinicians are more likely than ever to encounter marijuana usage in their practice settings and must be prepared to manage this reality and associated risks.
About the Instructor
Bradley Gillespie, PharmD.
Trained as a clinical pharmacist, Brad has practiced in an industrial setting for the past 20+ years. His initial role was as a Clinical Pharmacology and Biopharmaceutics reviewer at FDA, followed by 15 years of leading Early Development programs in the pharma/biotech/nutritional industries. In addition to his industrial focus, he remains a registered pharmacist and enjoys mentoring drug development scientists and health professionals; leading workshops and developing continuing education programs for pharmacy, nursing and other medical professionals.
In addition to states that accept ANCC, Elite is an approved provider of continuing education in nursing by: Alabama, Provider #ABNP1418 (valid through March 1, 2021); California Board of Registered Nursing, Provider #CEP15022; District of Columbia Board of Nursing, Provider # 50-4007; Florida Board of Nursing, Provider #50-4007; Georgia Board of Nursing, Provider #50-4007; and Kentucky Board of Nursing, Provider #7-0076 (valid through December 31, 2019). This CE program satisfies the Massachusetts Board’s regulatory requirements as defined in 244 CMR5.00: Continuing Education.
Elite is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.